1. INTRODUCTION:

Messenger RNA (mRNA) technology has fundamentally changed the field of medicine, exemplified by the fast development and public access to COVID-19 vaccines.

However, the potential uses of mRNA therapies extend far beyond vaccines; they have applications into cancer immunotherapy, gene editing, protein replacement therapies, and rare genetic diseases.¹ Given the versatility and ease of design, and safety as it relates to translational potential, it positions mRNA-based therapeutics amongst the most modern tools in the biomedical toolkit.² The central dogma of molecular biology - DNA to RNA to protein - substantiates the premise of mRNA therapeutics, as mRNA-based approaches can act completely independent of genomic therapies by not requiring delivery to the nucleus, as the cytoplasm contains the translational machinery of the cell. As a result, mRNA and mRNA-based approaches also reduce the potential risks that are normally associated with genomic integration that occur with DNA-based gene therapies.³ More than 150mRNA therapeutic candidates, aimed at treating cancers, infectious diseases, metabolic disorders, and genetic diseases are currently in various stages of clinical testing, following the successful optimization and deployment of mRNA in COVID-19 vaccines.⁴ Innovations to support mRNA stability; modulation of mRNA immunogenicity; and incorporation of delivery systems, for mRNA such as lipid nanoparticles (LNPs), have continued to support mRNA translational applications.⁵

2. mRNA Design and Delivery Technologies:

The effective design of mRNA therapeutics relies on two important pillars: the engineering of the mRNA molecule itself and the delivery technology for transporting it into target cells. Each of these elements is decisive for the authors to consider in determining the pharmacokinetics, safety, and efficacy of the final therapeutic product.⁶

2.1 Structure of Synthetic mRNA

A functional synthetic mRNA consists of the following important components:

· 5′ Cap: Provides stability to the mRNA and allows for efficient ribosome binding.

· 5′ Untranslated Region (5′ UTR): Helps regulate translational efficiency.

· Coding Domain Sequence (CDS): Provides the sequence encoding the therapeutic protein or antigen.

· 3′ Untranslated Region (3′ UTR): Serves a regulatory role in mRNA half-life and localization.

· Poly(A) Tail: Adds stability and promotes translation.⁷

Figure 1: Schematic of a synthetic mRNA molecule

2.2 Delivery Systems:

Lipid Nanoparticles (LNPs) An encumbrance for mRNA therapeutics is the instability and the susceptibility to degradation by extracellular RNAses. Naked mRNA is unable to easily cross cell membranes and is rapidly degraded in circulation.⁸ Therefore, LNPs have become the leading delivery technology.

Lipid nanoparticle composition:

The structure of lipid nanoparticles typically has 4:

· Ionizable lipids: Aid in endosomal escape

· Phospholipids: Build structure

· Cholesterol: Facilitates membrane fusion

· PEG-lipids: Extend circulation times

The components self-assemble mRNA and form a stable, nanoscale structure that protects the cargo and then releases it to the cytosol upon cellular uptake.⁹

Mechanism:

1. Endocytosis by Target Cells

2. Endosomal Escape

3. Cytoplasmic Release

4. Translation by Ribosomes

2.3 Novel Delivery Strategies Outside of LNPs:

LNPs are effective at delivering mRNA, but they can also activate innate immunity to cause inflammation. Therefore, new delivery systems are being evaluated:

Table 1: Delivery based Key Feature of Current Application^9,10,11

Delivery Platform	Key Features	Current Applications
Polymer-based nanoparticles	High stability, modifiable surfaces	Cancer immunotherapy
Exosomes	Natural carriers with low toxicity	Neurodegenerative diseases
Cell-penetrating peptides	Small and customizable	Gene therapy
DNA-based nanostructures	Scaffolded control	Antigen delivery systems

3: Clinical Uses of mRNA Technology beyond Vaccines:

Cancer Imunotherapy:

mRNA-based cancer vaccines are changing the landscape in the field of oncology by providing an avenue for rapidly producing patient-specific expression of tumor antigens. The personalized neoantigen vaccine approach to mRNA vaccination produces mRNA that is specific for the tumor mutations from the patient being treated for the cancer, and thereby stimulates cytotoxic T cell activity. Trials of Moderna's mRNA-4157 (in combination with Keytruda) have shown a positive impact on overall survival in patients with melanoma¹¹, and BioNTech’s BNT111 is also being dosed in melanoma and prostate cancer trials with early indications of a positive immunogenic response.¹²

1. Immune-Modulatory mRNA Therapies: Another strategy is delivering mRNA that encodes immune-activating molecules such as IL-12, IFN-γ, or GM-CSF that reprogram the tumor microenvironment to elicit a strong anti-tumor immune response.¹² These are particularly useful in tumors resistant to standard checkpoint blockers.

2. Gene Editing with mRNA: mRNA is also a safe and transient carrier for CRISPR/Cas9 components for gene editing without genomic integration. mRNA delivers the Cas9 protein and guide RNAs for genome editing with precision. For example, Vertex and CRISPR Therapeutics’ CTX001 utilizes Cas9 mRNA to treat β-thalassemia and sickle cell anemia.¹¹ Moreover, there are several studies with mRNA delivered CRISPR for in vivo gene editing of the PCSK9 (cholesterol regulation) and TTR (amyloidosis) genes.¹³

3. Protein Replacement Therapy: mRNA is currently being studied for the endogenous synthesis of either deficient or defective proteins, particularly in inherited metabolic diseases. Given mRNA's intracellular localization and glycosylation capabilities, unlike typical enzyme-based therapies, clinical implementations include mRNA-CFTR for Cystic Fibrosis and mRNA-G6PC for glycogen storage disease.^14,15

4. Treating Rare Genetic Disease: mRNA-based therapeutics provide a new route to precision treatment of monogenic rare diseases. For example, NTLA-2001 (by Intellia) delivers a CRISPR/Cas9 to the disease target, the TTR gene, via mRNA and LNP, and tolerability and protein modulation were achieved >87% with a single dose.¹⁶ Other efforts involve treatments directed to diseases such as phenylketonuria (PAH-mRNA), surfactant B deficiency, and hemophilia A (FVIII-mRNA).

5. Overview of Clinical Trials: Many clinical trials demonstrate the adaptability of mRNA beyond infectious disease. Examples include BNT122 (a neoantigen melanoma vaccine, BioNTech; Phase II), mRNA-3705 (a treatment for Propionic Acidemia, Moderna; Phase I), and CV8102 (solid tumors, cytokine delivery, CureVac; Phase I). Clinical trials examples provide evidence of a growing range of mRNA therapeutics.¹⁷

4: Challenges, Innovations and Future Outlook:

1. Concerns on Safety and Immunogenicity: The integration potential of mRNA into the host genome is not a risk. Nevertheless, there is risk of some inflammatory side effects due to low-level activation of innate immunity. For example, double-stranded RNA (dsRNA) which may be a contaminant from in vitro transcription, can activate TLR3/7/8 and the RIG-I pathway. Developers attempted to minimize immunogenicity by 2-nucleoside-modification of mRNA (e.g., pseudouridine, 5mC), or through development of mRNA purification processes, including high-performance liquid chromatography (HPLC).¹⁸ Nevertheless, overstimulation poses an immune challenge in non-oncology indications and can be a challenge to balance for target efficacy with immune tolerance.

2. Delivery systems: Lipid nanoparticles (LNPs) are still the most efficient form of non-viral vector for systemic delivery of mRNA.¹⁹ However, targeting, liver, tropism, cytotoxicity, and complement activation all provide challenges for safety and efficacy.²⁰ Novel form formulations continue to be examined for organ-specific delivery as well as escape intracellular organelles. Formulations with improved ability to specifically target lung, heart, brain, and immune target cells is a major area of focus.²¹

3. Manufacturing and Scaling Constraints: mRNA vaccines displayed scalability during the COVID-19 pandemic; however, therapeutics must meet different quality control requirements. Key manufacturing and scaling challenges include large-scale GMP synthesis, capping efficiency, dsRNA (double-stranded RNA) drainage and removal, and sterile LNP (lipid nanoparticle) encapsulation. In combination with these challenges, cost and cold chain warehousing (recruiting −20°C or −80°C storage) becomes another major hurdle, particularly for potential global deployment in the context of rare disease therapies.²²

4. Stability and Storage Issues: mRNA is inherently unstable and subject to hydrolysis, oxidation and enzymatic degradation. Storing perishable mRNA compounds contributes to limited access in low-middle-income regions. To address instability, developers have shifted their focus towards lyophilized mRNA, dry powder inhalers and formulations that are room-temperature stable by utilizing new excipients like trehalose and PEGylated lipids.²³

5. Future Outlook: mRNA therapeutics are likely to expand beyond rare diseases and cancer into regenerative medicine, autoimmune disorders, and allergy treatments. Combined with AI-driven design, machine learning for sequence optimization, and synthetic biology, mRNA could become a universal therapeutic modality—highly customizable, rapidly scalable, and tissue-targetable.²⁴

5: Industrial Landscape and Market Analysis:

1. Post-COVID Surge in Investment: The success of COVID-19 mRNA vaccines by Pfizer-BioNTech and Moderna triggered a global investment surge in mRNA therapeutics. Venture capital funding in mRNA companies crossed $6 billion in 2021, compared to just $600 million in 2019 (IQVIA, 2022). Post-pandemic, the industry is pivoting toward therapeutic indications, including rare diseases, oncology, and cardiovascular conditions.²⁵

2. Major Biotech Players and Pipelines: Besides Moderna and BioNTech, other key players include CureVac, Arcturus Therapeutics, Genova Biopharmaceuticals, Translate Bio (acquired by Sanofi), and eTheRNA. Moderna alone is developing over 45 mRNA-based therapeutics, targeting indications such as CMV, RSV, melanoma, myocardial ischemia, and cystic fibrosis. BioNTech has a robust oncology pipeline, including autologous neoantigen vaccines and mRNA-encoded CAR T-cell therapies (Moderna Pipeline Report, 2023).

3. Collaborative RandD Ecosystem: Pharma giants like Pfizer, Sanofi, AstraZeneca, and Roche are entering mRNA through collaborations or acquisitions. For instance, Sanofi’s acquisition of Translate Bio ($3.2 billion) reflects strategic movement into mRNA platforms. Similarly, Moderna’s partnership with Merck on personalized cancer vaccines has entered Phase II trials. Academic-industry collaborations are also expanding, particularly in mRNA immunotherapy and gene repair.²⁶

4. Manufacturing and Supply Chain Infrastructure: The pandemic accelerated the construction of GMP-grade mRNA manufacturing sites, with players like Moderna and BioNTech building modular plants in Africa, Asia, and Europe. These facilities aim to support local production of mRNA therapeutics and vaccines. The rise of contract development and manufacturing organizations (CDMOs) like Catalent, Lonza, and Wuxi Biologics is democratizing access to scalable mRNA production platforms.

5. Cutting-edge Technologies – Self-Amplifying mRNA (saRNA): saRNA contains the gene of interest as well as replicase machinery (often stably expressed from alphaviruses) which allows amplification of RNA in the cell. This can reduce doses for saRNA by 100-fold, and generates longer protein expression.²⁷ saRNA is being explored as cancer vaccines and pandemic influenza. Nonetheless, the safety and immunogenicity profiles are still being explored.

6. Circular mRNA (circRNA) – Next-Gen Stability: Circular RNA does not have free ends and so, by nature, are more resistant to exonucleases, which provides them increased intracellular half-lives. Synthetic circRNA can be designed to evade innate immune sensors to promote prolonged protein expression, independent of boosts. Early data in mice have shown a promising translation efficiency, and a means of controlling immunogenicity.²⁷

7. Regulatory and Ethical Considerations: The pace of development for mRNA technologies occurred prior to the development of regulatory frameworks. Questions remain regarding the long-term safety, potential off-target effects, and ethics of gene editing using mRNA/CRISPR systems with last resort options.

8. The FDA and EMA are actively trying to create a plan for the introduction of approval processes for nucleic acid-based drugs and medical devices while trying to maintain the degree of rigor with safety.²⁸

9. Market Forecast and Revenue Growth: According to a report by Market Research Future, the global mRNA therapeutics market is expected to grow from $39 billion in 2023 to $137 billion by 2030, at a CAGR of ~19.8%. Oncology will account for nearly 40% of total revenue, followed by rare diseases, cardiovascular therapy, and autoimmune disorders. Revenue from vaccines is expected to stabilize, while therapeutics will dominate growth (MRF, 2023).

Figure 2: Project Market Share by Therapeutic Area²⁸

10. Commercialization challenges: Despite a robust marketplace and optimism for mRNA applications beyond vaccines, there are significant challenges to commercialization such as patent complexity, reimbursement, and regulatory bottlenecks. The currently ongoing patent litigation between Moderna and Pfizer/BioNTech, regarding the use of lipid nanoparticle (LNP) technologies, is an example of the battles over intellectual property driving the maturation of a market. Beyond vaccines, orphan drug pricing, public acceptance, and cold chain logistics will affect the pace of commercialization for mRNA technology applications.²⁹

11. Regional Market: The United States continues to lead the way in terms of innovation and investment, followed by countries including Germany, and China and Japan. China has multiple companies, for example, Stemirna Therapeutics, Abogen, and Walvax, rapidly rising on the global stage as they invest in their domestic mRNA platform. Also notable is India, where Gennova launched Asia's first indigenously developed mRNA vaccine and plans to explore using mRNA technology for cardiovascular disease and rare diseases, indicating an emerging South-South collaboration.³⁰

12. Market Differentiation by Platform: In the mRNA ecosystem, companies are also differentiating themselves by not only indications but also platform characteristics with technologies such as saRNA, circRNA, mRNA-loaded exosomes, and organoid compatible delivery systems. Delivering improved expression profiles, dosing efficiency, and tissue specificity provides the case that mRNA platforms could be versatile across multiple therapeutic areas.³¹

6: Regulatory and Ethical Considerations

1. Advancement of the Regulatory Landscape: The regulatory framework for mRNA therapeutics is still developing. Therapeutics will require standardized pathways for full licensure and will not simply rely on the Emergency Use Authorizations (EUAs) issued for SARS-CoV-2 vaccines.³² Regulatory bodies (e.g., FDA, EMA, PMDA) are also currently developing guidance for mRNA drugs that will include aspects of quality control such as the mRNA construct, the delivery system, and in vivo expression levels.³²

2. Compliance and GMP Oversight: Unique aspects of mRNA drug products, including in vitro transcriptions of RNA, preparing lipid nanoparticles (LNPs), and maintaining cold chain logistics, require adherence to GMP protocols. For example, the FDA requires that mRNA drug products establish their process validations in detail. The European Medicines Agency also emphasizes the need for traceability of gene therapy medicinal products and batch consistency.³³ Facilities will have to ensure the integrity of the RNA, manage the endotoxin levels, and carry out sterility testing throughout manufacturing.

3. Differences in Global Regulatory Maturity: While US and EU regulators have progressed with the review of mRNA products, there exists a lack of regulatory maturity and infrastructure in emerging economies (e.g., Africa, Southeast Asia, South America) where plain and clear frameworks are missing. The WHO has initiated mRNA technology transfer hubs with particular emphasis on African and Latin American countries not only to find local manufacturing but also to prompt regulatory harmonization and knowledge transfer (World Health Organization, 2022).

4. Long-term Safety Monitoring: Ethical Concerns about Germline Editing: Most mRNA therapeutics will include non-integrative and somatic applications. However, mRNA delivery of CRISPR-Cas9 continues to raise concerns about unintended gene edited effects and germline alterations. Regulatory agencies continue to ban germline editing in humans, and growing calls for bioethics frameworks for mRNA-gene editing combinations have occurred.³⁴

5. Equity in Access and Distribution: A significant ethical issue is equity in global/international access to mRNA therapies. Wealthy nations were able to monopolize access to vaccines during the COVID era, and people's concerns about vaccine nationalism were present. If there are not established frameworks or commitments to manufacture and distribute mRNA therapeutics from both the public and for-profit/privately funded sectors, there is a risk for inequity when mRNA therapeutics are scaled.³⁵ C-TAP and the mRNA hub that the WHO has created are two forms of frameworks aimed at creating equal access to mRNA therapeutics.

6. Intellectual Property (IP) Disputes and Transparency: Numerous notable patent cases in recent years—specifically Moderna v. Pfizer/BioNTech, and Arbutus v. Moderna over lipid nanoparticles (LNP) technologies—show the high-stakes competition for intellectual property (IP) in mRNA technology. If deviations from existing IP are raised during regulatory approvals, then treatments in question could be delayed. Some scholars have asked for an open source or open access mRNA platform like for mRNA's public health applications in response to events like pandemics and for neglected diseases.³⁶

7. Consent and Data Privacy in Personalized mRNA Treatments: Personalized mRNA vaccines (e.g., cancer vaccine) that go through a genomics sequencing process might raise issues regarding ownership, storage, and privacy of the patient data. Effective data protection regulations, like GDPR (Europe) and HIPAA (U.S.), exist in some cases; however, a global consensus regarding issues of data privacy and consent for the ownership and storage of patient data is lacking. An emerging requirement of ethical review boards today—specifically for clinical trials using mRNA technology for personalized treatment—is proof of an explicit informed consent approach regarding patient data.

8. Public Confidence and Misinformation: The widespread misinformation that developed during the COVID pandemic (such as the misconception that mRNA alters DNA) has affected public trust and perception of mRNA therapy.³⁷

Thus, regulators and public health authorities will now have to consider how to provide transparency to the public while communicating science proactively to the public. Education will be vital in facilitating informed consent for future mRNA therapies and public uptake.³⁷

9. Animal Research and Animal Models: The ethical character of animal testing in mRNA research is receiving increased scrutiny, particularly regarding the need for in vivo efficacy and biodistribution studies.⁶⁷ In considering animal testing, researchers will evaluate alternative preclinical models such as organoids and computational models for safety testing, especially as 3Rs (Replacement, Reduction, Refinement) become a guiding principle of governing regulation in the biotech sphere.³⁸

7: Challenges in Delivery Systems for mRNA Therapeutics:

1. Intrinsic Instability of mRNA Molecules: The instability of mRNA molecules is due to their single strandedness, which increases their susceptibility to degradation by ribonucleases (RNases) in the environment. Without protection, naked mRNA will quickly degrade in vivo, meaning delivery systems usually need a protective delivery vehicle (lipid nanoparticle (LNP)) to increase delivery.³⁹ Failure to vague instability is fundamental to the success of any delivery system.

2. Efficient cellular internalization and escape from the endosome: For mRNA to have been successfully delivered, LNPs need to not only enter the cell, but they also need to escape the endosome before degradation. Many delivery systems, especially LNPs, run into the problem of becoming trapped in the endosome where that acidic conditions can also cause toxicity. While strategies have been created using ionizable lipids to disrupt endosomal membranes, this method still proves to be an inefficient step in delivery.⁴⁰

3. Immunogenicity of Delivery Systems: mRNA may be immunogenic by itself, but the delivery system - particularly synthetic or cationic lipids - may be responsible for eliciting innate immune activation and inflammation, as well as other side effects.¹⁵ Currently, research is being undertaken to engineer new cationic lipids to improve biocompatibility while also enhancing the efficacy of the mRNA.^8,5

4. Tissue-specific targeting difficulties:

Current RNA-delivery lipid nanoparticle carriers mostly deliver the mRNA to the liver due to hepatic uptake mechanisms. However, non-hepatic tissue types require dedicated or unique delivery strategies to deliver the mRNA to muscle, lung, brain, or tumors - each situation requires unique design, e.g. aiming drug at ligand receptor interactions, antibody decorated carriers or polymeric scaffolds,²¹Creating selectivity in biodistribution will be an important target for further use of these mRNA therapeutic modalities (beyond vaccines).⁴¹

5. Scale-up Manufacturing and Reproducibility: Although several delivery technologies like lipid nanoparticles (LNPs) can technically be prepared at laboratory scale, the practical translation of these to industrial or GMP-grade production has complications. Consumer preference dictates control over particle size, encapsulation efficiency, charge or polydispersity index. Furthermore, variability in formulation can impact the bioavailability and safety of the product. In this case, continuous microfluidic-based production may offer an appropriate alternative.⁴²

6. Biodegradability and Accumulation:

Certain synthetic delivery systems are not completely biodegradable and may accumulate in the tissue, posing a potential long-term safety issue, and thus, research is currently aiming to develop biodegradable polymers (for example, polyesters, PLGA) and cleavable ionizable lipids that breakdown when releasing their mRNA cargo, thereby reducing toxicity and improving clearance.³⁵

7. Cold Chain Dependence: Currently, most mRNA-LNP formulations are greatly influenced by temperature changes, and need to be stored at -20°C to -80°C, adding complexity to the logistics of transporting to sites of administration and especially in low resource settings¹⁷ newer studies report using lyophilization and thermostable excipients to increase stability at room temperature or standard refrigeration.³⁵

8. Nanotoxicology and Off-target Effects: Nanocarriers may lead to non-specific biodistribution/distribution to organs/organ accumulation, and/or unintentional activation of the immune system, and so the long-term effects of repeated mRNA-nanocarrier dosing are not well understood. Therefore, nanotoxicology profiling (hemolysis, complement activation, and cytokine release assays) in preclinical models is warranted.³⁷

9. Scarcity of Clinical-grade Lipids and Polymers: Specialty ionizable lipids and PEG-lipids for use in LNPs are not readily accessible at GMP-grade for procurement. This presents a challenge to smaller biotech companies and academic centers conducting preclinical and clinical trials. Open-source platforms and international mRNA delivery consortia are striving to democratize access to essential building blocks.⁴³

10. Integration with the Next Wave of Modalities (such as CRISPR/Cas): The delivery of CRISPR components through mRNA is complicated by dual delivery: Cas mRNA and guide RNAs (gRNAs) must be co-packaged and delivered. Coordinating expression and avoiding off-target edits can add additional layers of complexity to mRNA delivery systems.⁴⁴

8: Advances in Next-Generation Delivery Platforms for mRNA Therapeutics:

1. Ionizable Lipid Nanoparticles (iLNPs): Originating from the traditional lipid nanoparticles, ionizable lipid nanoparticles have superior endosomal escape and decreased systemic toxicity. Unlike permanently charged cationic lipids, ionizable lipids are positively charged only in the acidic environment of endosomes, thus inadvertently disrupting membranes and assisting mRNA release to the cytoplasm. New generations of custom-designed lipids are driving enhanced efficiency in addition to attenuated inflammatory responses.⁴⁴

2. Hybrid Lipid-Polymer Nanoparticles (LPNs): Combining the favorable biocompatibility of a lipid with the structural integrity of a polymer, these hybrid nanoparticles confer advantages, such as high loading capacity of nucleic acids, prolonged circulation time, and significant preferential targeting to particular tissues.⁴⁵ Polymers, such as PLGA (poly (lactic-co-glycolic acid)) and PEI (polyethyleneimine) can be integrated into hybrid applications to fine-tune the surface charge and degradation.⁴⁶

3. Exosome Mediation for Delivery: Exosomes are naturally secreted vesicles thought to be involved in intercellular communication, and they can be engineered to carry mRNA molecules. Their innate biocompatibility, low immunogenicity, and capability to cross biological barriers (e.g., blood-brain barrier) make them attractive for mRNA delivery, particularly in neurodegenerative diseases or for brain-targeted therapy.⁴⁵

4. Virus-Like Particles (VLPs): VLPs share structural characteristics with viruses, but they are non-replicating. They have natural tropism, high uptake, and endosomal escape capabilities, which allows them to serve as an effective and efficient mRNA delivery platform. Engineered VLPs can express ligands or fusion peptides to target specific cells and at the same time minimize immune responses.⁴⁷

5. Cell-Penetrating Peptides (CPPs): Cell-penetrating peptides, including TAT peptide, penetratin, and Arg-rich motifs are being used in mRNA carriers to directly promote the mRNA's translocation across the plasma membrane. CPPs are capable of transporting large RNA cargo into cells and can also be fused to ligands or antibodies to target diseased tissues. CPPs hold great promise for oncology and personalized gene therapy.

6. Ultrasound and Electroporation-based Systems: Physical methods such as low-frequency ultrasound, microbubble-assisted cavitation, and electroporation have been optimized to transiently perforate cell membranes to facilitate greater mRNA uptake. The development of these systems is currently underway for localized delivery in dermatology, cardiology, and tumor microenvironments.⁴⁷

7. Nanogels and Hydrogel Systems: Hydrogel systems have the potential to provide localized sustained-release depots for mRNA delivery in wound healing, cartilage regeneration, and immunotherapy. Hydrogel systems can prevent the degradation of mRNA payloads and provide for spatiotemporal control of release, making them suitable vehicles in tissue engineering.^10,34

8. Aptamer-Conjugated Systems: Aptamers are short nucleic acids with secondary and tertiary structure that function as ligands to bind specifically to cell surface proteins. Attaching aptamers sample cell targeting to mRNA nanoparticles, which is especially beneficial for tumor targeting applications in cancer immunotherapy. Aptamer conjugated nanoparticles can deliver mRNA payloads to CD4 T cells, HER2 tumors, and also to angiogenic vasculature.³⁴

9. Biodegradable Cationic Polymers: Newer polymers such as poly (beta-amino esters) and poly (ortho esters) are fully biodegradable compared to traditional PEI, which creates a lower cytotoxicity while supporting robust immunotherapy through uptake, with comparable efficacy to traditional materials. The tunable degradable parameters may vary in charge density, hydrophilicity or hydrophobicity, and degradation time, allowing for a composite approach for a variety of therapeutics with similar efficacy.⁴⁸

Targeted organ-devoted delivery (SORT) LNPs:

One of the most exciting recent developments is Selective Organ Targeting (SORT) lipid nanoparticles (LNPs) that alter a LNPs lipid composition, redirecting biodistribution toward the lungs, spleen, or brain, instead of just the liver. SORT LNPs now allow tissue-specific gene expression from a systemic dose without the need for invasive delivery. This overcomes one of the major challenges in mRNA therapeutics, as noted.³⁵

Table 3: Comparative Features of Delivery Systems

Delivery Platform	Efficiency	Immuno-genicity	Targeting Ability	Biodegrad-ability
Ionizable LNPs	High	Low	Moderate	Moderate
Hybrid LPNs	Moderate	Moderate	High	High
Exosomes	Moderate	Very Low	High	Natural
VLPs	High	High	High	Variable
CPPs	Moderate	Low	Customizable	Moderate
Electroporation	Low	High	Localized	N/A
Hydrogels	Moderate	Low	Localized	High
Aptamer-Conjugates	Moderate	Low	Very High	Variable
Biodegradable Polymers	Moderate	Very Low	Variable	Very High
SORT LNPs	Very High	Low	Organs-specific	Moderate

9: Clinical Translation and Approved mRNA Therapeutics:

· COVID-19 as the Proof-of-Concept Moment: The Emergency Use Authorization (EUA) of Pfizer–BioNTech’s BNT162b2 and Moderna’s mRNA-1273 vaccines represented the first-ever regulatory approval of an mRNA-based drug in human medicine. These vaccines showed excellent efficacy, greater than 90%, and the ability to produce mRNA drugs a masse, package them for cold-chain transport, and develop them in record times. Each of these processes ultimately demonstrated the potential for mRNA drugs to be used more broadly as a therapeutic platform.⁴⁹

· Expanding Indications Beyond Infectious Disease: In addition to COVID-19, clinical trials of mRNA vaccines are occurring for several potential indications to protect patients against influenza, Zika, cytomegalovirus (CMV), and HIV. Moderna’s mRNA-1010 (influenza) and mRNA-1647 (CMV) are currently in Phase 2/3 trials. Both vaccines are using modified nucleosides in the mRNA molecule to limit activation of the innate immune system, and hopefully improve tolerability.¹⁵

· Cancer Immunotherapy: mRNA as a Neoantigen Vaccine In oncology, personalized cancer vaccines using mRNA derived from tumor neoantigens are presently in clinical trials. The first neoantigen therapeutics, BNT122 by BioNTech in partnership with Genentech, have entered Phase 2 volume trials for treatment of melanoma and gastrointestinal cancers. These therapeutics generally stimulate robust cytotoxic T-cell responses against unique tumor antigens from the host patient.

· Rare Genetic Disorders: Protein Replacement Treatment Clinical studies are being conducted on using mRNA to replace proteins for rare metabolic disorders. For example, Moderna's mRNA-3704 is aimed at methylmalonic acidemia (MMA) and mRNA-3927 is aimed at propionic acidemia (PA). The objectives of the trials are to induce the expression of absent protein and restore enzyme activity utilizing systemic mRNA delivery.²

· Cardiovascular Indications: Regenerative AngiogenesisAZD8601- an mRNA coding for VEGF-A- developed by AstraZeneca and Moderna demonstrated potential safety and efficacy in a Phase 1 study for ischemic heart disease. The mRNA was delivered via local application during coronary artery bypass grafting (CABG) surgery to induce the generation of new blood vessels.⁵⁰

· Pulmonary and Cystic Fibrosis based Therapies: Translate Bio (recently acquired by Sanofi) is working on inhalable mRNA therapies for cystic fibrosis, specifically addressing the defective expression/transport of CFTR protein. Although in early clinical development, these studies target lung localized delivery of therapeutics to address the underlying defective protein.¹⁵

· Hematological Disorders: Hemophilia and Sickle Cell Development of mRNA-based expression of coagulation factors (FVIII/FIX) is being investigated for hemophilia A/B. For sickle cell disease, mRNA-based gene editing systems such as CRISPR/Cas9 mRNA guide RNA are being evaluated for ex vivo alteration of hematopoietic stem cells.⁵¹

· Neurodegenerative Disorders: Although it is still early research, mRNA therapy is under evaluation for neurodegenerative diseases such as Parkinson’s, ALS, and Alzheimer’s, utilizing exosomes or lipid carriers that can cross the blood-brain barrier. Several animal models indicate that mRNA can express neuroprotective proteins or modify inflammation.^5,8

· Current Clinical Trial Landscape: Over 150 mRNA-based clinical trials are currently registered worldwide at various phase levels. The platform developers dominating this trial landscape are Moderna, CureVac, BioNTech, and Arcturus with increasing engagement from academic-industry collaborations. Most of these trials are in the areas of oncology, rare diseases, and infectious diseases, with strong movement towards personalized or individualized medicine trajectories (ClinicalTrials.gov, 2024).

· Regulatory Challenges and Evolving Pathways: mRNA therapeutics are still grappling with challenges related to long-term safety assessments, regulatory alignment, and scaling of GMP-compliant manufacturing. The U.S. FDA has begun to publish guidance on nucleic acid therapeutics, but broader global alignment and establishing therapeutic specific pharmacovigilance mechanisms are still evolving (EMA, 2023).

10: Challenges and Future Prospects:

a) Issues Related to Stability and Storage:

Molecular instability is one of the most common challenges with mRNA therapeutics. The intrinsic nature of mRNA predisposes it to hydrolysis and enzymatic degradation, which experienced during congruence in the early examples of vaccines necessitated their storage under ultra-cold conditions (-70°C) (Pardi et al., 2018). The progression of new formulations using modified lipid carriers has allowed vaccines to be stored at 2 - 8 °C, though more innovations will be necessary to develop shelf-stable formulations for lower-resourced settings.⁴¹

b) Limitations Associated with Delivery Systems:

While LNPs have been effective in delivering mRNA, they tend to distribute to the liver and spleen, which may not be desirable for extra-hepatic tissue targeting.⁵² Also, repeat dosing may result in immune responses against the components of the LNP composite which reduce the overall effectiveness of the product overtime. Innovative delivery systems using targeted ligands, SORT molecules, and biodegradable polymers will be required to alleviate this.³⁵

c) Immunogenicity and Off-target Effects:

Some mRNA modifications, such as pseudouridine, reduce innate immune activation. While most modifications to eliminate innate immune activation, residual recognition of mRNA may still result in activation of TLR7/8 and RIG-I. Therefore, transfection of mRNA that continues to activate TLR7/8 or RIG-I may result in inflammation or unwanted side effects.³⁸ When utilized as CRISPR mRNA, off-target editing is an important aspect of safety associated with gene editing applications, particularly with long-lived tissues such as neurons or stem cells.⁵³

d) Cost Structure and Manufacturing Scale:

Manufacturing scalable, reproducible mRNA synthesis with GMP compliance is costly. Advances in cell-free enzymatic synthesis platforms have occurred, but costs for high purity modified nucleotides, cap analogs, and lipids remain high.³⁶ The emergence of modular RNA manufacturing facilities may help in decentralizing future manufacturing.³

e) Regulation and Intellectual Property:

The relative intellectual property (IP) landscape for mRNA technologies is fragmented. Patent litigation related to mRNA structures, LNPs, and cap analogs between key players (Moderna, CureVac, Arbutus, etc.) can slow down or impede open innovation (Check Hayden, 2021). Additionally, regulatory frameworks for personalized mRNA therapeutics (e.g., neoantigen vaccines) remains a work in progress.

f) Ethical Challenge and Access:

Personalized mRNA vaccines, gene editing tools, and tissue-targeted therapies bring new ethical challenges⁸ Issues such as data privacy (i.e., genomics sequence), equity in accessibility, and the potential for the enhancement of health without therapy will not be easy to address as national collaborations on preventing significant inequities or monopoly will be required (e.g. WHO mRNA Technology Transfer Hub, 2023).

g) Environmental and Safety Surveillance:

As mRNA therapies become more widespread, their long-term effects on the human microbiota, immune modulation, and the environmental impact of biologics (waste) will need to be researched, especially since mRNA (as a therapeutically modified agent) is not considered a "natural" compound, and therefore greater monitoring and assessment of biocompatibility might be needed occurring over time.²⁰

h) Next Generation mRNA Therapies:

Forward-looking will be self-amplifying mRNA (saRNA) that require ultra-low doses, and circular mRNA with superior stability, as well as switchable mRNA systems employing riboswitches that allow controlled expression.²⁷ Collectively, these platforms offer more than just vaccines; they may offer smart biologics, biosensors, and cellular circuitries capable of real-time modulation of disease.

9. Constructing a Global mRNA Development Ecosystem:

The COVID-19 pandemic revealed a pressing demand for decentralized mRNA manufacturing hubs. Initiatives such as the World Health Organization and Afrigen Biologics are undertaking important initiatives aimed at addressing equitable access to vaccines, for example, by establishing decentralized vaccine developer capabilities in Africa, South America, and Asia. These decentralization efforts are in part aligned with the principles of open science (e.g., Open mRNA) that intend to eliminate reliance on proprietary technology and establish public-good platforms (Nature Biotech, 2022).

10. Future Imagination - Programmable Medicine:

Ultimately, mRNA is not just a molecule - mRNA is a programmable biologic. Future applications of this technology could lead mRNA to be used as synthetic gene networks, in vivo reprogramming agents, and living therapeutics. The combination of in-silico-designed mRNA, synthetic biology, and precision delivery may lead to medicine being dynamic, adaptive, and responsive to each patient's conditions in real-time.⁵⁴

DISCUSSION:

The use of mRNA technology, which gained public awareness following its use in the COVID-19 vaccines, is now being analyzed for novel therapeutic use in autoimmune diseases. Scientists are exploring mRNA to program cells to produce specific proteins in a predictable manner to modulate immune responses with high specificity. This opens pathways for tolerogenic mRNA vaccines to re-educate the immune system to assess self-antigens as tolerant, and perhaps reverse diseases such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes. Research on methods of delivery of mRNA including immune targeting, safety, and sustained tolerance and stability of mRNA will continue to define its therapeutic promise within the field of autoimmune disease.

CONCLUSION:

mRNA technology has become a powerful platform in biomedicine, moving forward beyond vaccine development to other therapeutic applications of mRNA technology for cancer therapy, genetic diseases, and regenerative medicine. The programable, speed of development, and scalable uses of technology make it an ideal pathway to personalized medicine and emergency preparedness. However, challenges remain. Stability, immune response, and delivery methods are all scientific challenges that must still be tackled. In addition, intellectual property disputes, manufacturing capacity challenges, and lack of equitable access will all affect the commercial and global health landscape of the mRNA field. as the field progresses, we will continue to see innovations in mRNA technology, including self-amplifying mRNA and circular RNA, plus efforts to transfer technology to low- and middle-income countries to enhance access and innovation. With continued dedication from the scientific, industry, and policymaking communities, mRNA is expected to become a cornerstone for next-generation therapeutics with the potential to disrupt modern medicine on a global scale.

REFERENCES:

1. Ketaki Shinde, Sonam Bendre, Niraj Kale, Suhit Gilda. The mRNA Vaccine Heralds a New Era in Vaccinology. Asian Journal of Pharmacy and Technology. 2022; 12(3): 257-5

2. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat Rev Drug Discov. 2018; 17(4): 261–279. https://doi.org/10.1038/nrd.2017.243

3. Haabeth OA, Blake TR, McKinlay CJ, et al. Local delivery of ox40l, Cd80, and Cd86 mRNA kindles global anticancer immunity. Cancer Res. 2019; 79(7): 1624–1634.

4. Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019; 27(4): 710–728. https://doi.org/10.1016/j.ymthe.2019.02.012

5. Wajid Ahmad, Rihan Jawed. An Updated Review on Preparation and Characterization of Solid Lipid Nanoparticles. Asian Journal of Pharmacy and Technology; 12(4):313-9.

6. Krienke, C., Kolb, L., Diken, E., Streuber, M., Kirchhoff, S., Bukur, T. and Sahin, U. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 2021; 371(6525): 145–153. https://doi.org/10.1126/science.aay3638

7. Schneeberger A, Tenenbaum L. mRNA-based gene therapy: a new era for rare genetic diseases? Gene Ther. 2020; 27(9):411–416. https://doi.org/10.1038/s41434-020-0142-6

8. Wajid Ahmad, Rihan Jawed. An Updated Review on Preparation and Characterization of Solid Lipid Nanoparticles. Asian Journal of Pharmacy and Technology; 12(4):313-9.

9. Hou, X., Zaks, T., Langer, R., and Dong, Y. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials. 2021; 6(12): 1078–1094. https://doi.org/10.1038/s41578-021-00358-0

10. Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019; 10: 594.

11. A. K. Das Mohapatra. Determinants of Corporate Capital Structure: Evidence from Indian Industries. Asian J. Management. 2012; 3(1): 10-13

12. Leuschner F, Dutta P. mRNA therapy in cardiovascular disease. Circ Res. 2021; 128(6): 811–26.

13. Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O’Connell D, Walsh KR, Wood K, Phillips J. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine. 2021 Aug 5; 385(6): 493-502.

14. Kormann MS, Hasenpusch G, Aneja MK, et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol. 2011; 29(2): 154–57.

15. Pardi, N., Hogan, M. J., Porter, F. W., and Weissman, D. mRNA vaccines — a new era in vaccinology. Nature Reviews Drug Discovery. 2018; 17(4): 261–279. https://doi.org/10.1038/nrd.2017.243

16. Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O’Connell D, Walsh KR, Wood K, Phillips J. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine. 2021 Aug 5; 385(6): 493-502

17. A. K. Das Mohapatra. The Changing Role of HR in Corporate Value Creation. Asian J. Management. 2012; 3(2): 59-61

18. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov. 2014; 13(10): 759–80

19. Mohammed Rizwan B., Sucharitha P., Jaibiba P. Nano Probes for mRNA Detection than using in-situ Hybridization and hence the use of Nano Particles in Cancer Diagnosis and Therapy. Asian J. Pharm. Tech. 2013; 3(4): 213-217

20. Verbeke R, Lentacker I, De Smedt SC, Dewitte H. Three decades of messenger RNA vaccine development. Nano Today. 2019; 28: 100766. https://doi.org/10.1016/j.nantod.2019.100766

21. Van Hoecke L, Verbeke R, Dewitte H, Lentacker I. The status of messenger RNA-based vaccines in the race against COVID-19. Curr Opin Pharmacol. 2021; 60:1–9.

22. Maruggi G, Zhang C, Li J, Ulmer JB, Yu D. mRNA as a transformative technology for vaccine development to control infectious diseases. Mol Ther. 2019; 27(4): 757–772. https://doi.org/10.1016/j.ymthe.2019.01.020

23. Kauffman KJ, Dorkin JR, Yang JH, et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 2015; 15(11): 7300–7306.

24. Kowalski, P. S., Rudra, A., Miao, L., and Anderson, D. G. (). Delivering the messenger: Advances in technologies for therapeutic mRNA delivery. Molecular Therapy. 2019; 27(4): 710–728. https://doi.org/10.1016/j.ymthe.2019.02.012

25. Wang H, Zhu X, Yan Y, et al. mRNA therapy for myocardial infarction. Curr Pharm Des. 2020; 26(36): 4645–56.

26. Effect of protocatechuic acid on TNF- mRNA level in the liver of Hepatotoxicity rats. Mary Charlet R., Anuradha R.. Research J. Pharma. Dosage Forms and Tech. 2012; 4(6): 324-327.

27. Blakney AK, Ip S, Geall AJ. An update on self-amplifying mRNA vaccine development. Vaccines (Basel). 2021; 9(2): 97.

28. Fotin-Mleczek M, Duchardt KM, Lorenz C, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother. 2011; 34(1):1–15.

29. Granados-Riveron JT, Aquino-Jarquin G. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2. Biomed Pharmacother. 2021; 142: 111953. https://doi.org/10.1016/j.biopha.2021.111953

30. Thess A, Grund S, Mui BL, et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther. 2015; 23(9): 1456–1464.

31. Phua, K. K., Nair, S. K., and Leong, K. W. Messenger RNA (mRNA) nanoparticle tumour vaccination. Nanoscale. 2014; 6(14): 7715–7729. https://doi.org/10.1039/C4NR00668G

32. Jackson NAC, Kester KE, Casimiro D, Gurunathan S, DeRosa F. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines. 2020; 5:11.

33. Lorenz C, Fotin-Mleczek M, Roth G, et al. Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol. 2011; 8(4): 627–636.

34. Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019; 10: 594.

35. Ramachandran S, Chen J, et al. Nanoparticle-delivered mRNA therapy in cardiac regeneration. Trends Cardiovasc Med. 2022; 32(2): 115–25.

36. Sahin U, Türeci Ö. mRNA-based cancer immunotherapy. Immunity. 2020; 52(4):597–613.

37. Mahardian Rahmadi, Zuhaela Iqbal, Ikbar Nanda Pratama, Rifky Anindita Karunia, Arina Derry Puspitasari, Khoirotin Nisak, Aniek Setiya Budiatin. PEG-4000 Ameliorates morphine-induced constipation in mice through inhibition of AQP-3 mRNA Expression. Research Journal of Pharmacy and Technology. 2023; 16(7): 3331-8

38. Scangos K, Weissman D, Karikó K. mRNA technology: the dawn of a new era in vaccinology and therapeutics. Nat Biotechnol. 2022; 40(5): 678–85.

39. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov. 2014; 13(10): 759–80.

40. Kaczmarek, J. C., Patel, A. K., Kauffman, K. J., Fenton, O. S., Webber, M. J., Heartlein, M. W., and Anderson, D. G. (2016). Polymer–lipid nanoparticles for systemic delivery of mRNA to the lungs. Angewandte Chemie International Edition, 55(44), 13808–13812. https://doi.org/10.1002/anie.201606524

41. G. Sindhu. A Study on Employer Branding Strategies for Talent Retention. Asian J. Management. 2016; 7(1): 23-26

42. Nance KD, Meier JL. Modifications in an emergency: the role of N1-methylpseudouridine in COVID-19 vaccines. ACS Cent Sci. 2021; 7(5): 748–756. https://doi.org/10.1021/acscentsci.1c00173

43. Kaczmarek, J. C., Patel, A. K., Kauffman, K. J., Fenton, O. S., Webber, M. J., Heartlein, M. W., and Anderson, D. G. (2016). Polymer–lipid nanoparticles for systemic delivery of mRNA to the lungs. Angewandte Chemie International Edition, 55(44), 13808–13812. https://doi.org/10.1002/anie.201606524

44. Ramachandran, S., Satapathy, S. R., Dutta, T. mRNA therapeutics in regenerative medicine: New dawn for functional tissue recovery. Advanced Drug Delivery Reviews. 2022; 182: 114115. https://doi.org/10.1016/j.addr.2021.114115

45. Wang Y, Su HH, Yang Y, et al. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther. 2013; 21(2):358–367.

46. Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X. mRNA vaccine: a potential therapeutic strategy. Mol Cancer. 2021; 20(1): 33.

47. Feldman RA, Fuhr R, Smolenov I, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults. Vaccine. 2019; 37(25): 3326–3334.

48. Reichmuth AM, Oberli MA, Jeklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016; 7(5): 319–334

49. Andries O, Mc Cafferty S, De Smedt SC, Weiss R, Sanders NN, Kitada T. N1-methyl-pseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines. Mol Ther Nucleic Acids. 2015; 1:e83. https://doi.org/10.1038/mtna.2014.8

50. Ghosh S, Brown A, Han H, et al. mRNA delivery for cardiovascular disease therapy. Adv Drug Deliv Rev. 2022; 183: 114127

51. Zhang H, Onuma K, Peterson S, et al. Targeted delivery of mRNA to pancreatic β-cells using engineered exosomes. Mol Ther. 2021; 29(5): 1620–1632.

52. Freyn AW, da Silva JR, Rosado VC, et al. mRNA-based vaccines combine individualized and off-the-shelf strategies. Front Immunol. 2021; 12: 682481

53. Hewitt SL, Bai A, Bailey D, et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs. Sci Transl Med. 2019; 11(477): eaat9143.

54. Kowalski, P. S., Rudra, A., Miao, L., and Anderson, D. G. Delivering the messenger: Advances in technologies for therapeutic mRNA delivery. Molecular Therapy. 2019; 27(4): 710–728. https://doi.org/10.1016/j.ymthe.2019.02.012

Received on 09.04.2025 Revised on 15.08.2025

Accepted on 24.10.2025 Published on 22.01.2026

Available online from January 29, 2026

Asian J. Pharm. Res. 2026; 16(1):1-11.

DOI: 10.52711/2231-5691.2026.00001

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.

Company	Focus Areas	Notable Programs
Moderna	Vaccines, Oncology, Rare Diseases	CMV, RSV, Personalized Cancer Vaccines
BioNTech	Oncology, Infectious Disease	Neoantigen Therapy, Solid Tumor Immunotherapy
CureVac	Oncology, Respiratory, Rare Diseases	Seasonal Flu, Cystic Fibrosis
Arcturus	saRNA Therapeutics, Liver Disease	LUNAR-CF, Self-Amplifying mRNA
Sanofi/Translate Bio	Vaccine Expansion, mRNA Platform	COVID-19, Flu, and RSV Programs
Gennova	Cardiovascular, Infectious Disease (India)	Indigenous COVID Vaccine, Stroke Therapeutics
eTheRNA	mRNA Immunotherapy and Exosome Delivery	Cancer Vaccines